Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age

Phase 4 Completed 21 enrolled Shire Takeda Development Center Americas, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This long-term study will provide Elaprase treatment to children enrolled in this study and will utilize data from both enrolled patients and Hunter Outcome Survey (HOS) patient registry data to conduct the primary growth analysis to assess changes in height and weight in patients with Mucopolysaccharidosis II (Hunter syndrome) MPS II.

Timeline

Start: 2015-10-28
Primary completion: 2025-07-29
Completion: 2025-07-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	idursulfase	Protein / enzyme biologic	0.5 mg/kg	Intravenous

Indications

No indication recorded.